Watson Pharmaceuticals, a leading specialty pharmaceutical company, announced that its subsidiary, Watson Laboratories has received final approval from the Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Bupropion Hydrochloride Extended-Release Tablets (XL) in the 150 mg strength.

 

Bupropion Hydrochloride Extended-Release Tablets is the generic equivalent to GlaxoSmithKline's Wellbutrin XL product, which is indicated for the treatment of major depressive disorder. Watson intends to launch the product immediately.

Watson Pharmaceuticals, headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.